Clinical Trial Detail

NCT ID NCT03377556
Title Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Southwest Oncology Group
Indications

lung squamous cell carcinoma

Therapies

Talazoparib

Age Groups: adult child senior

Additional content available in CKB BOOST